welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Autologous Cell Therapy Approach for Duchenne Muscular Dystrophy using PiggyBac Transposons and Mesoangioblasts
source: Molecular Therapy
year: 2018
authors: Iyer PS, Mavoungou LO, Ronzoni F, Zemla J, Schmid-Siegert E, Antonini S, Neff LA, Dorchies OM, Jaconi M, Lekka M, Messina G, Mermod N
summary/abstract:Duchenne muscular dystrophy (DMD) is a lethal muscle-wasting disease currently without cure. We investigated the use of the PiggyBac transposon for full-length dystrophin expression in murine mesoangioblast (MABs) progenitor cells. DMD murine MABs were transfected with transposable expression vectors for full-length dystrophin and transplanted intramuscularly or intra-arterially into mdx/SCID mice. Intra-arterial delivery indicated that the MABs could migrate to regenerating muscles to mediate dystrophin expression. Intramuscular transplantation yielded dystrophin expression in 11%-44% of myofibers in murine muscles, which remained stable for the assessed period of 5 months. The satellite cells isolated from transplanted muscles comprised a fraction of MAB-derived cells, indicating that the transfected MABs may colonize the satellite stem cell niche. Transposon integration site mapping by whole-genome sequencing indicated that 70% of the integrations were intergenic, while none was observed in an exon.
Muscle resistance assessment by atomic force microscopy indicated that 80% of fibers showed elasticity properties restored to those of wild-type muscles. As measured in vivo, transplanted muscles became more resistant to fatigue. This study thus provides a proof-of-principle that PiggyBac transposon vectors may mediate full-length dystrophin expression as well as functional amelioration of the dystrophic muscles within a potential autologous cell-based therapeutic approach of DMD.
organization: University of Lausanne, Switzerland; University of Geneva, Switzerland; Institute of Nuclear Physics, Polish Academy of Sciences, Poland; Swiss Institute of Bioinformatics, Switzerland; University of Milan, ItalyDOI: 10.1016/j.ymthe.2018.01.021
read more
rareRelated
-
Why my patient advocacy organization is investing in CRISPRIn last year’s action film “Rampage,...
-
NIH Awards $86 Million to Improve Genome Editing TechniquesSomatic Cell Genome Editing support is a...
-
CureDuchenne Ventures Commits $500,000 to 4D Molecular Therapeutics to Advance Next-Generation AAV Delivery of Gene ...CureDuchenne, a national venture phila...
-
How AAV Gene Transfer Works – General Audiencehttps://youtu.be/SUOskEqLpyY...
-
Sarepta Therapeutics Announces that Phase 1/2a Duchenne Muscular Dystrophy (DMD) Micro-Dystrophin Gene Therapy Trial...Sarepta Therapeutics, Inc., a commercia...
-
Bespoke Is Often Better: How Scientists Are Customizing Gene TherapyWhen it comes to products from suits to ...
-
Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapyDuchenne muscular dystrophy (DMD) is a p...